Which has preferable earnings and valuation, SERA or AGMB?

Sera Prognostics has higher revenue and earnings than AgomAb Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Sera Prognostics $80K 1,005.98 -$31.93M -$0.67 N/A AgomAb Therapeutics N/A N/A -$70.77M N/A N/A

Does the media prefer SERA or AGMB?

In the previous week, AgomAb Therapeutics had 14 more articles in the media than Sera Prognostics. MarketBeat recorded 17 mentions for AgomAb Therapeutics and 3 mentions for Sera Prognostics. Sera Prognostics' average media sentiment score of 1.79 beat AgomAb Therapeutics' score of 1.31 indicating that Sera Prognostics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Sera Prognostics 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive AgomAb Therapeutics 6 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer PRLD or SERA?

In the previous week, Prelude Therapeutics had 2 more articles in the media than Sera Prognostics. MarketBeat recorded 5 mentions for Prelude Therapeutics and 3 mentions for Sera Prognostics. Sera Prognostics' average media sentiment score of 1.79 beat Prelude Therapeutics' score of -0.14 indicating that Sera Prognostics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Prelude Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 2 Very Negative mention(s) Neutral Sera Prognostics 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Does the media favor SERA or LRMR?

In the previous week, Sera Prognostics had 1 more articles in the media than Larimar Therapeutics. MarketBeat recorded 3 mentions for Sera Prognostics and 2 mentions for Larimar Therapeutics. Sera Prognostics' average media sentiment score of 1.79 beat Larimar Therapeutics' score of 0.91 indicating that Sera Prognostics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Sera Prognostics 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Larimar Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer ABEO or SERA?

In the previous week, Sera Prognostics had 1 more articles in the media than Abeona Therapeutics. MarketBeat recorded 3 mentions for Sera Prognostics and 2 mentions for Abeona Therapeutics. Sera Prognostics' average media sentiment score of 1.79 beat Abeona Therapeutics' score of 1.07 indicating that Sera Prognostics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Abeona Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Sera Prognostics 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Does the media favor SERA or FATE?

In the previous week, Fate Therapeutics had 3 more articles in the media than Sera Prognostics. MarketBeat recorded 6 mentions for Fate Therapeutics and 3 mentions for Sera Prognostics. Sera Prognostics' average media sentiment score of 1.79 beat Fate Therapeutics' score of 0.48 indicating that Sera Prognostics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Sera Prognostics 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Fate Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Sera Prognostics (SERA) Competitors

$2.06 +0.03 (+1.23%)

As of 10:28 AM Eastern

Compare

SERA vs. AGMB, PRLD, LRMR, ABEO, and FATE

Should you buy Sera Prognostics stock or one of its competitors? Sera Prognostics's main competitors and comparable companies include AgomAb Therapeutics (AGMB), Prelude Therapeutics (PRLD), Larimar Therapeutics (LRMR), Abeona Therapeutics (ABEO), and Fate Therapeutics (FATE). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Sera Prognostics compare to AgomAb Therapeutics?

Sera Prognostics (NASDAQ:SERA) and AgomAb Therapeutics (NASDAQ:AGMB) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, analyst recommendations, risk, profitability, dividends, valuation, institutional ownership and earnings.

AgomAb Therapeutics has a net margin of 0.00% compared to Sera Prognostics' net margin of -47,475.72%. AgomAb Therapeutics' return on equity of 0.00% beat Sera Prognostics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sera Prognostics	-47,475.72%	-46.71%	-34.06%
AgomAb Therapeutics	N/A	N/A	N/A

54.6% of Sera Prognostics shares are owned by institutional investors. 11.3% of Sera Prognostics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Sera Prognostics has higher revenue and earnings than AgomAb Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sera Prognostics	$80K	1,005.98	-$31.93M	-$0.67	N/A
AgomAb Therapeutics	N/A	N/A	-$70.77M	N/A	N/A

In the previous week, AgomAb Therapeutics had 14 more articles in the media than Sera Prognostics. MarketBeat recorded 17 mentions for AgomAb Therapeutics and 3 mentions for Sera Prognostics. Sera Prognostics' average media sentiment score of 1.79 beat AgomAb Therapeutics' score of 1.31 indicating that Sera Prognostics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Sera Prognostics	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
AgomAb Therapeutics	6 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Sera Prognostics presently has a consensus target price of $5.50, suggesting a potential upside of 169.61%. AgomAb Therapeutics has a consensus target price of $37.50, suggesting a potential upside of 325.65%. Given AgomAb Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe AgomAb Therapeutics is more favorable than Sera Prognostics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sera Prognostics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.67
AgomAb Therapeutics	0 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.88

Summary

AgomAb Therapeutics beats Sera Prognostics on 7 of the 13 factors compared between the two stocks.

How does Sera Prognostics compare to Prelude Therapeutics?

Prelude Therapeutics (NASDAQ:PRLD) and Sera Prognostics (NASDAQ:SERA) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, analyst recommendations, valuation, profitability, risk, media sentiment, dividends and earnings.

Sera Prognostics has lower revenue, but higher earnings than Prelude Therapeutics. Prelude Therapeutics is trading at a lower price-to-earnings ratio than Sera Prognostics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Prelude Therapeutics	$12.14M	23.40	-$99.50M	-$0.73	N/A
Sera Prognostics	$80K	1,005.98	-$31.93M	-$0.67	N/A

79.7% of Prelude Therapeutics shares are owned by institutional investors. Comparatively, 54.6% of Sera Prognostics shares are owned by institutional investors. 49.2% of Prelude Therapeutics shares are owned by company insiders. Comparatively, 11.3% of Sera Prognostics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

In the previous week, Prelude Therapeutics had 2 more articles in the media than Sera Prognostics. MarketBeat recorded 5 mentions for Prelude Therapeutics and 3 mentions for Sera Prognostics. Sera Prognostics' average media sentiment score of 1.79 beat Prelude Therapeutics' score of -0.14 indicating that Sera Prognostics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Prelude Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	2 Very Negative mention(s)	Neutral
Sera Prognostics	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Prelude Therapeutics presently has a consensus target price of $8.75, indicating a potential upside of 145.79%. Sera Prognostics has a consensus target price of $5.50, indicating a potential upside of 169.61%. Given Sera Prognostics' stronger consensus rating and higher possible upside, analysts clearly believe Sera Prognostics is more favorable than Prelude Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Prelude Therapeutics	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50
Sera Prognostics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.67

Prelude Therapeutics has a beta of 0.97, meaning that its share price is 3% less volatile than the broader market. Comparatively, Sera Prognostics has a beta of 1.06, meaning that its share price is 6% more volatile than the broader market.

Prelude Therapeutics has a net margin of 0.00% compared to Sera Prognostics' net margin of -47,475.72%. Sera Prognostics' return on equity of -46.71% beat Prelude Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Prelude Therapeutics	N/A	-75.35%	-44.39%
Sera Prognostics	-47,475.72%	-46.71%	-34.06%

Summary

Sera Prognostics beats Prelude Therapeutics on 11 of the 17 factors compared between the two stocks.

How does Sera Prognostics compare to Larimar Therapeutics?

Sera Prognostics (NASDAQ:SERA) and Larimar Therapeutics (NASDAQ:LRMR) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their profitability, institutional ownership, earnings, media sentiment, analyst recommendations, risk, dividends and valuation.

Sera Prognostics presently has a consensus target price of $5.50, indicating a potential upside of 169.61%. Larimar Therapeutics has a consensus target price of $10.33, indicating a potential upside of 378.40%. Given Larimar Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Larimar Therapeutics is more favorable than Sera Prognostics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sera Prognostics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.67
Larimar Therapeutics	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	2 Strong Buy rating(s)	3.00

54.6% of Sera Prognostics shares are owned by institutional investors. Comparatively, 91.9% of Larimar Therapeutics shares are owned by institutional investors. 11.3% of Sera Prognostics shares are owned by insiders. Comparatively, 4.0% of Larimar Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

In the previous week, Sera Prognostics had 1 more articles in the media than Larimar Therapeutics. MarketBeat recorded 3 mentions for Sera Prognostics and 2 mentions for Larimar Therapeutics. Sera Prognostics' average media sentiment score of 1.79 beat Larimar Therapeutics' score of 0.91 indicating that Sera Prognostics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Sera Prognostics	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Larimar Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Larimar Therapeutics has a net margin of 0.00% compared to Sera Prognostics' net margin of -47,475.72%. Sera Prognostics' return on equity of -46.71% beat Larimar Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sera Prognostics	-47,475.72%	-46.71%	-34.06%
Larimar Therapeutics	N/A	-137.39%	-97.65%

Sera Prognostics has a beta of 1.06, suggesting that its share price is 6% more volatile than the broader market. Comparatively, Larimar Therapeutics has a beta of 0.68, suggesting that its share price is 32% less volatile than the broader market.

Sera Prognostics has higher revenue and earnings than Larimar Therapeutics. Sera Prognostics is trading at a lower price-to-earnings ratio than Larimar Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sera Prognostics	$80K	1,005.98	-$31.93M	-$0.67	N/A
Larimar Therapeutics	N/A	N/A	-$165.67M	-$1.95	N/A

Summary

Sera Prognostics beats Larimar Therapeutics on 9 of the 16 factors compared between the two stocks.

How does Sera Prognostics compare to Abeona Therapeutics?

Abeona Therapeutics (NASDAQ:ABEO) and Sera Prognostics (NASDAQ:SERA) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their profitability, earnings, institutional ownership, analyst recommendations, risk, dividends, media sentiment and valuation.

Abeona Therapeutics has a net margin of 0.00% compared to Sera Prognostics' net margin of -47,475.72%. Abeona Therapeutics' return on equity of -41.69% beat Sera Prognostics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Abeona Therapeutics	N/A	-41.69%	-30.36%
Sera Prognostics	-47,475.72%	-46.71%	-34.06%

Abeona Therapeutics has higher revenue and earnings than Sera Prognostics. Abeona Therapeutics is trading at a lower price-to-earnings ratio than Sera Prognostics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Abeona Therapeutics	$5.82M	44.41	$71.18M	-$1.09	N/A
Sera Prognostics	$80K	1,005.98	-$31.93M	-$0.67	N/A

In the previous week, Sera Prognostics had 1 more articles in the media than Abeona Therapeutics. MarketBeat recorded 3 mentions for Sera Prognostics and 2 mentions for Abeona Therapeutics. Sera Prognostics' average media sentiment score of 1.79 beat Abeona Therapeutics' score of 1.07 indicating that Sera Prognostics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Abeona Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Sera Prognostics	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Abeona Therapeutics currently has a consensus target price of $21.00, indicating a potential upside of 364.60%. Sera Prognostics has a consensus target price of $5.50, indicating a potential upside of 169.61%. Given Abeona Therapeutics' higher probable upside, equities analysts clearly believe Abeona Therapeutics is more favorable than Sera Prognostics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Abeona Therapeutics	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67
Sera Prognostics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.67

80.6% of Abeona Therapeutics shares are held by institutional investors. Comparatively, 54.6% of Sera Prognostics shares are held by institutional investors. 7.1% of Abeona Therapeutics shares are held by company insiders. Comparatively, 11.3% of Sera Prognostics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Abeona Therapeutics has a beta of 1.31, indicating that its share price is 31% more volatile than the broader market. Comparatively, Sera Prognostics has a beta of 1.06, indicating that its share price is 6% more volatile than the broader market.

Summary

Abeona Therapeutics beats Sera Prognostics on 9 of the 16 factors compared between the two stocks.

How does Sera Prognostics compare to Fate Therapeutics?

Sera Prognostics (NASDAQ:SERA) and Fate Therapeutics (NASDAQ:FATE) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, valuation, analyst recommendations, media sentiment, earnings, profitability, risk and dividends.

Sera Prognostics currently has a consensus price target of $5.50, indicating a potential upside of 169.61%. Fate Therapeutics has a consensus price target of $5.90, indicating a potential upside of 195.00%. Given Fate Therapeutics' higher probable upside, analysts plainly believe Fate Therapeutics is more favorable than Sera Prognostics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sera Prognostics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.67
Fate Therapeutics	1 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.38

Sera Prognostics has a beta of 1.06, indicating that its share price is 6% more volatile than the broader market. Comparatively, Fate Therapeutics has a beta of 2.52, indicating that its share price is 152% more volatile than the broader market.

54.6% of Sera Prognostics shares are owned by institutional investors. Comparatively, 97.5% of Fate Therapeutics shares are owned by institutional investors. 11.3% of Sera Prognostics shares are owned by insiders. Comparatively, 4.7% of Fate Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Fate Therapeutics has a net margin of -1,941.09% compared to Sera Prognostics' net margin of -47,475.72%. Sera Prognostics' return on equity of -46.71% beat Fate Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sera Prognostics	-47,475.72%	-46.71%	-34.06%
Fate Therapeutics	-1,941.09%	-65.08%	-41.73%

In the previous week, Fate Therapeutics had 3 more articles in the media than Sera Prognostics. MarketBeat recorded 6 mentions for Fate Therapeutics and 3 mentions for Sera Prognostics. Sera Prognostics' average media sentiment score of 1.79 beat Fate Therapeutics' score of 0.48 indicating that Sera Prognostics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Sera Prognostics	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Fate Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Sera Prognostics has higher earnings, but lower revenue than Fate Therapeutics. Sera Prognostics is trading at a lower price-to-earnings ratio than Fate Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sera Prognostics	$80K	1,005.98	-$31.93M	-$0.67	N/A
Fate Therapeutics	$6.65M	36.04	-$136.32M	-$1.05	N/A

Summary

Sera Prognostics beats Fate Therapeutics on 9 of the 17 factors compared between the two stocks.

Get Sera Prognostics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SERA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

SERA vs. The Competition

Export

Metric	Sera Prognostics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$81.46M	$3.88B	$7.26B	$13.10B
Dividend Yield	N/A	3.65%	2.52%	22.89%
P/E Ratio	-3.08	13.21	275.54	25.58
Price / Sales	1,018.30	1,131.68	557.67	80.26
Price / Cash	N/A	118.50	77.16	53.04
Price / Book	1.06	17.16	10.81	6.02
Net Income	-$31.93M	-$22.65M	$3.49B	$380.34M
7 Day Performance	-0.24%	-4.64%	-3.00%	-3.19%
1 Month Performance	3.25%	-12.66%	-7.48%	-6.07%
1 Year Performance	-34.44%	8.08%	3.18%	-3.77%

Sera Prognostics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
SERA Sera Prognostics	2.5168 of 5 stars	$2.07 +1.2%	$5.50 +166.3%	-33.6%	$81.46M	$80K	N/A	72	News Coverage Positive News
AGMB AgomAb Therapeutics	3.902 of 5 stars	$8.84 +1.7%	$37.50 +324.2%	N/A	$314.90M	N/A	N/A	62	Positive News Gap Up
PRLD Prelude Therapeutics	2.0096 of 5 stars	$3.81 +1.1%	$8.75 +129.7%	+184.8%	$300.86M	$12.14M	N/A	79	News Coverage Analyst Forecast
LRMR Larimar Therapeutics	2.5947 of 5 stars	$2.78 -2.8%	$10.33 +271.7%	-49.2%	$297.11M	N/A	N/A	71
ABEO Abeona Therapeutics	3.007 of 5 stars	$5.01 -2.0%	$21.00 +319.2%	-16.5%	$292.21M	$5.82M	N/A	226

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:SERA) was last updated on 10/14/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Sera Prognostics (SERA) Competitors

SERA vs. AGMB, PRLD, LRMR, ABEO, and FATE

How does Sera Prognostics compare to AgomAb Therapeutics?

Summary

How does Sera Prognostics compare to Prelude Therapeutics?

Summary

How does Sera Prognostics compare to Larimar Therapeutics?

Summary

How does Sera Prognostics compare to Abeona Therapeutics?

Summary

How does Sera Prognostics compare to Fate Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SERA vs. The Competition

Sera Prognostics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Sera Prognostics (SERA) Competitors

SERA vs. AGMB, PRLD, LRMR, ABEO, and FATE

How does Sera Prognostics compare to AgomAb Therapeutics?

Is SERA or AGMB more profitable?

Do institutionals and insiders hold more shares of SERA or AGMB?

Which has preferable earnings and valuation, SERA or AGMB?

Does the media prefer SERA or AGMB?

Do analysts rate SERA or AGMB?

Summary

How does Sera Prognostics compare to Prelude Therapeutics?

Which has preferable valuation & earnings, PRLD or SERA?

Do insiders & institutionals believe in PRLD or SERA?

Does the media prefer PRLD or SERA?

Do analysts rate PRLD or SERA?

Which has more volatility and risk, PRLD or SERA?

Is PRLD or SERA more profitable?

Summary

How does Sera Prognostics compare to Larimar Therapeutics?

Do analysts prefer SERA or LRMR?

Do institutionals and insiders believe in SERA or LRMR?

Does the media favor SERA or LRMR?

Is SERA or LRMR more profitable?

Which has more risk and volatility, SERA or LRMR?

Which has better valuation & earnings, SERA or LRMR?

Summary

How does Sera Prognostics compare to Abeona Therapeutics?

Is ABEO or SERA more profitable?

Which has higher valuation & earnings, ABEO or SERA?

Does the media prefer ABEO or SERA?

Do analysts prefer ABEO or SERA?

Do institutionals & insiders believe in ABEO or SERA?

Which has more volatility & risk, ABEO or SERA?

Summary

How does Sera Prognostics compare to Fate Therapeutics?

Do analysts recommend SERA or FATE?

Which has more risk & volatility, SERA or FATE?

Do institutionals and insiders have more ownership in SERA or FATE?

Is SERA or FATE more profitable?

Does the media favor SERA or FATE?

Which has stronger earnings & valuation, SERA or FATE?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SERA vs. The Competition

Sera Prognostics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools